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APOBEC1 (A1) is a cytidine deaminase involved in the regulation of lipids in the small 17 
intestine.  HSV-1 is a ubiquitous pathogen that is capable of infecting neurons in the 18 
brain, causing encephalitis. Here, we show that A1 is induced during encephalitis in 19 
neurons of rats infected with HSV-1.  In A1-stably expressing cells, HSV-1 infection 20 
resulted in significantly reduced virus replication when compared with infection in control 21 
cells.  Infectivity could be restored to levels comparable to those observed in control 22 
cells if A1 expression was silenced by specific A1 shRNA.  Moreover, cytidine 23 
deaminase activity appeared to be essential for this inhibition and lead to an impaired 24 
accumulation of viral mRNA transcripts and DNA copy number.  The sequencing of the 25 
viral gene UL54 DNA, extracted from infected A1-expressing cells, revealed G to A and 26 
C to T transitions, indicating that A1 associates with HSV-1 DNA.  Taken together, our 27 
results demonstrate a model in which A1 induction during encephalitis in neurons may 28 
aid to thwart HSV-1 infection. 29 
 30 
 31 




The human apolipoprotein b editing catalytic polypeptide (ABOBEC) family is a group of 34 
zinc-dependent DNA and RNA cytidine deaminases and consists of AID, APOBEC1 35 
(A1), APOBEC2 (A2), seven APOBEC3s (A3A-H), and APOBEC4 (A4). A1, the first 36 
APOBEC to be discovered, is known to introduce a premature stop codon into host 37 
apolipoprotein B mRNA in the gastrointestinal tract, an event critical for lipid metabolism 38 
(17, 39, 60). The editing by A1 is highly precise and specifically converts C to U at 39 
position 6666 of the apolipoprotein B mRNA substrate (45). Along with apobec 1 40 
complementation factor ACF, these two proteins constitute the minimal required 41 
components necessary for the editing of apolipoprotein B mRNA in vitro (36). 42 
Cytidine deaminases as antiviral factors first came into the limelight after A3G was 43 
identified as a cellular restriction factor capable of inhibiting HIV-1 dissemination in the 44 
absence of HIV-1 virus infectivity factor (vif) (55). This molecule was later shown to 45 
inhibit retrovirus infection by inducing massive hypermutation of the murine leukemia 46 
virus (MLV) genome (22). Further detailed studies revealed that APOBEC molecules 47 
are packaged into HIV-1 virions in virus producer cells via a specific interaction with gag 48 
and viral RNA and then exert their deaminase activity in subsequent target cells on a 49 
single ssDNA intermediate synthesized by the reverse transcriptase (3, 27, 54). Editing 50 
can lead to non-synonymous mutations, such as premature stop codons, in critical 51 
proteins (e.g. reverse transcriptase) necessary for virus replication and infectivity, 52 
severely impairing the next round of infection (53, 63). Extensive studies to assess the 53 
antiviral nature of these APOBEC enzymes have been performed across a broad range 54 
of retroviruses and the hepatitis B virus (HBV) (7, 21, 34, 35, 41, 42, 49, 55, 57).  55 
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Herpes simplex virus (HSV) is an enveloped, dsDNA virus and a member of the genus 56 
alphaherpesviridae. One in every 250,000 to 500,000 individuals infected with HSV type 57 
1 (HSV-1) or type 2 (HSV-2) experiences a devastating disease known as HSV 58 
encephalitis (HSE), characterized by acute inflammation and/or hemorrhaging in the 59 
central nervous system (CNS) (61). HSV-1 is the predominant causative agent of 60 
sporadic encephalitis in western countries and it is estimated to be responsible for over 61 
90 % of HSE cases (61). 62 
In this study, we show a novel finding that A1 expression is induced during HSV-1 63 
infection in neurons of infant rat brains, more than 30 % of which were able to recover 64 
from HSE. Moreover, an investigation into the potential antiviral role of A1 in vitro 65 
revealed that A1 inhibited virus replication directly by mainly targeting viral DNA in a 66 
deaminase dependent manner, resulting in a stall of virus replication. To the best of our 67 
knowledge, this is the first report implicating the potential antiviral function of A1 against 68 
herpes viruses in the context of HSE. 69 
  70 
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Materials and methods 71 
Cells, plasmids, viruses and infection. Vero and RS cells were maintained in DMEM 72 
and supplemented with FCS and antibiotics as previously described (4). Rat A1 cDNA 73 
was obtained by RT PCR of mRNA derived from HSV-1-infected rat brain tissue and 74 
inserted into pcDNA3.1/Zeo(+) (Invitrogen). An A1 mutant, E63A, was generated by 75 
site-directed mutagenesis using a QuickChange® II Site-Directed Mutagenesis Kit 76 
(Stratagene).  HA-tagged empty vector, A1-WT, or E63-mutant DNA were transfected 77 
into RSC and then cultured for 10 days in the presence of Zeocin.  Colonies were then 78 
screened and confirmed for protein expression by western blotting with an anti-HA Mab.  79 
GFP-expressing replication-competent HSV-1, YK333 (59), was used as previously 80 
described (4).  YK333 HSV-1 was created by the intergenic insertion of a GFP 81 
expressing cassette between UL3 and UL4 of the virus genome.  Green fluorescence 82 
can be detected after HSV infects host cells and starts viral gene expression (59); 83 
however, since this event occurs before viral DNA replication, the GFP signal detected 84 
in these cells is not indicative of HSV-1 progeny production. For inhibition of HSV-1, we 85 
added 25 μg/ml of acyclovir (Sigma-Aldrich, St. Louis, MO, USA) in culture medium. 86 
Generation of shRNA  and shRNA-expressing cells. shRNA plasmids were 87 
generated by cloning A1 specific or luciferase control ORF targeted sense and 88 
antisense sequences  into a pBAsi-hU6 Puromycin vector (TaKaRa), via BamH1 and 89 
XbaI restriction sites.  The targeted A1 and luciferase sequences are as follows: A1- 90 
736, 5’-GATCCCCGACGCTCCGTTACCCGGTTACGTGTGCTG 91 




AAAT-3’; Luciferase, 5’-94 
GATCCCCGTGCGTTGTTGGTGTTAATACGTGTGCTGTCCGTATTGGCA 95 
CCAGCAGCGCACTTTTTGGAAAT-3’.  A1-expressing RSCs were transfected with the 96 
shRNA plasmids, respectively, using lipofectamine 2000, selected by puromycin for 97 
individual clones and finally analyzed by western blotting for the suppression of A1. 98 
Animal models and tissue collection. Fourteen-day-old Wistar Hannover GALAS rats 99 
(CLEA Japan, Inc.) were anaesthetized and then intracranially inoculated with 1.0 x 106 100 
TCID50 HSV-1 (YK333), or phosphate-buffered saline (PBS) as a negative control. Rats 101 
exhibiting a range of symptoms were classified into four groups as described in Table 1. 102 
For histological examinations, tissue samples were fixed by immersion in 4% PFA and 103 
processed as described before (4). All animal experiments were carried out according to 104 
the guidelines for animal experimentation at Kyoto University. 105 
Transcriptome analysis. RNA was prepared from rat brains using an RNeasy 106 
extraction kit (QIAGEN) and transcriptome analysis was performed using a GeneChip 107 
Rat Genome 230 2.0 Array (Affymetrix) according to the manufacturer’s instructions. 108 
Microarray data was analyzed using Gene Spring software (Agilent). 109 
Real-time PCR. Nucleic acids were extracted as previously described (4).   For the 110 
analyses of HSV-1 mRNA products, 1 μg of RNA was reverse transcribed using a 111 
QuantiTect Reverse Transcription Kit (QIAGEN), according to the manufacturer’s 112 
instructions.  The cDNA (50 ng) was used as a template to amplify UL54 (immediate 113 
early), UL30 (early), and UL27 (late) genes by real-time PCR using a Power 114 
SYBRGreen PCR Master Mix (Applied Biosystems).  The threshold was set to a value 115 
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of 1.00, and the number of cycles required to reach the threshold cycle, Ct, was 116 
determined and then normalized with the Ct of the housekeeping gene, GAPDH.  The 117 
HSV-1 DNA copy number was measured as previously described (4).  Thermocycler 118 
conditions for the real-time PCR reaction are as follows: 95°C for 10 min, (95°C for 15s, 119 
60°C for 1 min) x 40 cycles.  The primers used for real-time PCR are as follows: A1 120 
Forward, 5’-ACCACGCAGATCCTCGAAAT-3’;  A1 Reverse, 5’-121 
TCTTGCTCCGTCATGATCTGG-3’; HSV-1 UL54 Forward,  5’-122 
CCGCGACGACCTGGAATCGG-3’; HSV-1 UL54 Reverse: 5’-123 
GGCGAGCGGCGTCGAGTATC-3’; HSV-1 UL30 Forward, 5’-124 
AGAGGGACATCCAGGACTTTGT-3’; HSV-1 UL30 Reverse,  5’-125 
CAGGCGCTTGTTGGTGTAC-3’; HSV-1 UL27 Forward, 5’- 126 
TCGCCTTTCGCTACGTCAT-3’; HSV-1 UL27 Reverse, 5’- 127 
GGTTCTTGAGCTCCTTGGTGG-3’; GAPDH Forward, 5’ -128 
ACTAAAGGGCATCCTGGGCTA-3’; GAPDH Reverse: 5’ -129 
TGGAAGAATGGGAGTTGCTGT- 3’. 130 
Immunohistochemistry and antibodies. Brain sections and culture cells were treated 131 
as described before (4, 30). The following primary and secondary antibodies were used: 132 
goat anti-apobec1 polyclonal antibody (Pab) (Santa Cruz Biotechnology), rabbit anti-133 
HSV-1 Pab (DakoCytomation), mouse anti-MAP2 monoclonal antibody (Mab) (Upstate), 134 
anti-HA Mab (Roche), Alexa Fluor 594-conjugated anti-goat IgG (Invitrogen), Cy5-135 
conjugated anti-mouse IgG or Alexa Fluor 647-conjugated streptavidin (Invitrogen). 136 
Nuclei were stained using Hoechst33342 (Invitrogen). Each sample was examined 137 
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under a confocal laser microscope (TCS SP2 AOBS, Leica Microsystems) using 405, 138 
543, 633 nm excitations with 10x, 20x and 40x objectives. 139 
Sequencing analysis of UL54. Nested PCR of UL54 was carried out with Pfu Ultra II 140 
Fusion DNA polymerase (Stratagene). In the first round of PCR, 100 ng of template 141 
cDNA or DNA, derived from either HSV-1 infected A1-expressing or control cells, was 142 
used with the appropriate primers in a total volume of 25 μl under the following 143 
thermocycler conditions: 1 min at 98°C, (20 s at 98°C, 20 s at 57°C, and 30 s at 72°C) x 144 
35, and 3 min at 72°C.  For the second round of PCR, 2.5 μl of the first PCR reaction 145 
was used as a template in a total volume of 25 ul under the following thermocycler 146 
conditions:  1 min at 93.4°C, (20 s 93.4°C, 20 s at 57°C, and 30 s at 72°C) x 35, and 3 147 
min at 72°C.  The UL54 amplicon was cloned into a pUC19 vector and the DNA was 148 
extracted from transformed bacteria.  A BigDye® Terminator Cycle Sequencing Kit 149 
(v3.1) was next used and samples were read on an ABI® Prism 3130 sequencer.  150 
Sequences were analyzed using Sequencher 4.9 software.  The primers used for the 151 
nested PCR are listed as follows: First PCR UL54 forward, 5’-152 
AGCTTTGGCCGCAGCGCACA-3’; First PCR UL54Reverse, 5’-153 
GAGTTGCAATAAAAATATTTGCCGTGCAC-3’; Second PCR UL54 Forward, 5’- 154 
GGTCTAGAAGCTTTGGCCGCAGCGCACA-5’; Second PCR UL54 Reverse, 5’- 155 
ATCAAGCTTCCTCGCGCCTTCAGGTAGCA-3’.   156 
Statistical analysis. Statistical significance was determined using the student’s t test 157 
and χ2 analysis.  A p value of less than 0.05 was considered statistically significant. 158 




Survival rat model from encephalitis with intracranial HSV-1 inoculation 161 
In the past, rats have been reported to be useful models for examining HSE induced by 162 
both HSV-1 and HSV-2 and, depending on the age of the animal, there appears to be 163 
an age-dependent resistance to infection for survival (5, 15). In line with these reports, 164 
our preliminary studies revealed that infant GALAS rats before the age of 14 days old 165 
suffered from 100% mortality when infected by an intracranial injection of GFP-166 
expressing HSV-1 (YK333) (Supplementary Data 1). On the other hand, rats 18 days or 167 
older displayed 100% survival after HSV-1 inoculation.  Interestingly, the infection of 14 168 
day-old-rats resulted in half of the animals surviving (Supplementary Data 1). These 169 
results indicated that possible intrinsic factors expressed in rats from this age may help 170 
to protect against HSV.   171 
In order to the elucidate factors contributing to the survival of the HSV-1-infected 14-172 
day-old rats, we focused on the observed phenotype in this age group. We proceeded 173 
to inoculate 63 animals with HSV-1 for a more in-depth assessment of HSE.   We found 174 
that 17 HSV-1-injected rats (27%, indicated as severe in Table 1 and Figure 1A) died 175 
after showing severe signs of encephalitis such as weight loss and quadriplegia within 5 176 
days after inoculation. Fourteen injected rats (22%, indicated as mild in Table 1 and 177 
Figure 1A) died after showing a milder degree of weight loss and quadriplegia between 178 
5 and 7 days.  Interestingly, 24 injected rats (38.1%, indicated as survived in Table 1 179 
and Figure 1A) recovered from HSE after showing temporary paralysis; HSV-1 infection 180 
in these mice was confirmed by GFP+ and HSV-1+ regions. The final group of 8 injected 181 
rats did not exhibit symptoms of encephalitis and did not possess GFP+ and HSV-1+ 182 
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regions (indicated as healthy in Table 1).  The range of symptoms displayed by the rats 183 
indicated that some were able to cope with HSV-1 infection more than others, which we 184 
speculated to be due to the containment of virus infection. 185 
In the brain tissue of the severe and mild rats, taken at the time of death from HSE, we 186 
found vast hemorrhagic and necrotic damage (Figure 1A). Furthermore, disseminated 187 
GFP+ regions, which were confirmed as HSV-1+ cells by immunostaining with an anti-188 
HSV antibody, indicated massive spreading and a multifocal distributed infection in the 189 
brain, typical of encephalitis in human infants (Table 1 and Figure 1A) (61).  Severe and 190 
mild rats were also associated with extensive leukocyte infiltration by CD3+ T cells and 191 
CD68+ macrophages (Figure 1B, Red), however, brain samples from survived rats 192 
taken 36 h after the disappearance of paralysis showed less infiltration in parenchyma 193 
and fewer GFP+ cells (Table 1 and Figure 1B, 3rd row of panels). Meanwhile we could 194 
not detect pathological changes, GFP+ or HSV+ cells in the brains of mock-infected rats 195 
(in the bottom panels Figure 1A), confirming that the observed results were indeed 196 
dependent on HSV-1 infection. These data also indicated that limited but clear HSV-1 197 
infection occurred in the brain of the survived rats. 198 
To investigate whether our initial observation of reduced HSV-1 infection in survived 199 
rats was due to the control of HSV-1 dissemination over the course of infection or 200 
simply due to an inadequate initial infection, brain samples of survived rats were taken 201 
12, 24, and 36 h after the disappearance of paralysis, and the extent of GFP+ regions 202 
was determined. Results showed that the HSV-1-infected regions diminished over a 203 
span of 36 h, suggesting that the virus was being contained and cleared (Figure 1C). 204 
These data also suggest the existence of an anti-HSV factor(s) induced upon HSV-1 205 
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infection, which appears to be expressed in CNS parenchymal cells, including neurons 206 
or glia, since the number of invading lymphocytes and macrophages did not seem to 207 
correlate with clearance of the virus. 208 
Apolipoprotein B editing catalytic subunit 1 is induced during HSV-1 infection in 209 
brain tissue  210 
In order to identify potential candidate molecules which are induced in the brain upon 211 
HSV-1 infection, we isolated RNA from the GFP+ and neighboring regions of two 212 
survived rat brains at 4 and 6 days post infection (corresponding to 12 and 36 h after 213 
the disappearance of paralysis, respectively) and performed microarray analysis of 214 
mRNA from both survived or mock-infected rat brains. In comparing the level of mRNA 215 
from these rats, 47 genes showed augmented expression (Supplementary Data 2). 216 
Among them, the level of A1 mRNA was clearly increased by 4.59 and 41.6 fold at 4 217 
and 6 days post infection, respectively. 218 
Since A1 and related A3 family proteins are known to be strong inhibitors of HIV-1 219 
infection, we examined the possibility of an association between A1 and HSV-1 infection. 220 
From rat brain tissue, we were able to detect significantly elevated levels of A1 cDNA 221 
exclusively in HSV-1-infected rats by real-time PCR (Figure 2A). As expected, we 222 
confirmed high levels of A1 cDNA expression in the small intestine of mock and HSV-1- 223 
infected rats, where A1 is constitutively expressed (Figure 2E).  Immunofluorescence 224 
staining of brain tissue with an A1-specific antibody demonstrated A1+ staining only 225 




To further investigate the cell type specific expression of A1 after HSV-1 infection, we 228 
performed co-immunostaining with an anti-MAP2 (neuron-specific) and an anti-A1 229 
antibody. A1+ staining was predominantly observed in MAP2+ cells which were HSV-1 230 
infected but not in MAP2- cells, indicating that the A1 expression was induced in 231 
neurons within the HSV-1 infected brain (Figure 2B-D).  On the other hand, the 232 
expression levels of A1 in the small intestine were high regardless of HSV-1 infection 233 
(Figure 2F). These data suggested that A1 may serve as an intrinsic neuronal tissue 234 
factor for the control of HSV-1 infection in the CNS. 235 
A1 inhibits HSV-1 infection in a deaminase-dependent manner 236 
To examine the potential anti-HSV-1 activity of A1, we generated N-terminal HA-tagged 237 
wild type rat A1 (A1WT) stably-expressing rabbit skin cells (RSC). A1 is a zinc-dependent 238 
deaminase with 3 residues, (His61, Cys93, Cys96) needed for coordinating zinc binding 239 
and a glutamate residue at position 63 in the catalytic domain essential for cytidine 240 
deaminase activity (38). Hence, we also generated N-terminal HA-tagged A1 241 
deaminase-deficient mutant (A1E63A) stably-expressing RSC.  Control A1 (A1Ctrl) RSC 242 
were generated using an empty HA vector. Western blotting analysis using an anti-HA 243 
antibody confirmed that the expression of A1WT and A1E63A was equivalent in these cell 244 
lines (Figure 3A). Immunofluorescence staining of A1WT and A1E63A showed similar 245 
localization which was comparable to that in A1+ neuronal cells of HSV-1-infected brain 246 
tissue (Figure 2B and 3B, respectively). 247 
We next proceeded to assess the potential HSV-1 antiviral activity of A1 by infecting 248 
A1WT or A1E63A RSC with GFP-expressing HSV-1 at a MOI of 0.01. As shown in Figure 249 
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3C, the level of GFP expression was significantly attenuated in A1WT RSC in 250 
comparison to A1E63A and A1Ctrl RSC 48 h post infection. Interestingly, A1E63A cells also 251 
had a modest inhibitory effect on HSV-1, although this activity did not appear to be as 252 
potent as in wild type expressing RSC, suggesting a somewhat deaminase-independent 253 
inhibition mechanism (Figure 3C). When two different shRNA were used to specifically 254 
target A1WT, the infectivity of HSV-1 was restored and comparable to that observed in 255 
A1Ctrl (Figure 3D).  Overall, the low and high level of A1 protein expression resulting 256 
from specific shRNA (A1/736 and A1/1119) against A1 and control luciferase, 257 
respectively, correlated inversely with HSV-1 infectivity (Figure 3D) and suggested that 258 
A1 expression is essential for the inhibition of HSV-1 infection. 259 
In order to analyze the level of attenuation in HSV-1 replication, we looked at the virus 260 
titer of supernatants taken from A1ctrl, A1WT and AE63A cells infected at higher MOI. The 261 
virus titer of supernatant from HSV-1-infected A1WT cells was significantly attenuated 262 
when compared with that from empty vector or A1E63A stably expressing cells in a dose 263 
dependent manner (Figure 3E). Additionally, the A1E63A mutant also modestly 264 
attenuated virus titers, although not to the same extent as wild type A1. These data 265 
indicated again that cytidine deaminase activity was also crucial for potent inhibition to 266 
take place.  Taken together, even at a high MOI, HSV-1 replication was being 267 
significantly inhibited in A1WT expressing cells when compared with A1Ctrl RSC in a 268 
deaminase-dependent manner. 269 
A1 inhibits HSV-1 gene transcription and DNA replication 270 
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 HSV-1 gene expression is highly ordered and occurs in a cascade-dependent manner 271 
which is divided into three stages with the transcription products subdivided into 3 broad 272 
groups termed α, β, and γ, also known as immediate early (IE), early (E), and late (L), 273 
respectively (26). The α genes, produced soon after infection, promote β gene 274 
transcription and increase viral protein synthesis. Thereafter, β genes are transcribed 275 
and enhance DNA replication which, in turn, signals γ gene transcription for the 276 
production of viral proteins necessary for virion assembly (12). 277 
To better understand the mechanism by which A1 inhibits HSV-1 replication, we first 278 
examined the expression level of representative genes from α, β, and γ groups.  UL54, 279 
an α gene that plays a role in the shut off of host protein synthesis and also enhances 280 
viral gene expression, UL30, a β gene and the DNA polymerase responsible for DNA 281 
replication, and UL27, a γ gene and envelope glycoprotein, were analyzed by real-time 282 
PCR and normalized to GAPDH. As can be seen from the expression level of HSV-1 283 
cDNA extracted from A1Ctrl and A1WT stably expressing cells at 8 h post infection at a 284 
MOI of 0.01, all three genes analyzed were significantly lower in A1WT cells compared to 285 
A1Ctrl cells (Figure 4A). 286 
Given that α gene synthesis precedes DNA replication, we expected that the observed 287 
low level of the immediate early genes would affect HSV-1 DNA replication and, thus, 288 
the viral DNA copy number. Indeed, at 8 h post infection, the HSV-1 DNA copy number 289 
was nearly 4 times lower in the A1WT cells when compared with A1Ctrl cells (Figure 4B). 290 
As an additional control, infection of control RSC with a UV-inactivated virus did not 291 
result in viral DNA replication (Figure 4B). Altogether, our results indicated that A1 292 
affected viral gene expression and also DNA replication. 293 
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A1 induces mutations in HSV-1 DNA  294 
A1 homologues are putative inducers of mutations in retrovirus DNA and also in DNA of 295 
A1-expressing bacteria (8, 23, 28, 43, 48). Thus, to investigate the mechanism of A1-296 
dependent inhibition of HSV-1 gene expression, we looked at the potential editing of 297 
HSV-1 viral DNA. The UL54 DNA extracted from HSV-1-infected A1WT RSC showed 298 
evidence of both GA and CT transitions, indicating that plus and minus strands 299 
were being edited (Figure 5B). The majority of the 51 clones analyzed from A1WT RSC 300 
contained 1 mutation within the sequenced region; however, a few clones harbored 2 or 301 
3 mutations (Figure 5E). On the other hand, A1Ctrl derived clones showed no signs of 302 
mutations (Figure 5A and 5D), suggesting that the observed nucleotide changes were 303 
induced by A1. 304 
Given that rat A1 is also known to edit retroviral RNA, we looked at cDNA extracted 305 
from A1WT RSC 8 hpi at a MOI of 0.01 for evidence of additional deaminase activity (8). 306 
Similar to DNA sequencing results, GA and CT transitions in viral cDNA were 307 
observed, with the majority of clones containing 1 mutation, while clones with 2 or 3 308 
mutations were also observed (Figure. 5C and 5F). Interestingly, 1 clone contained 10 309 
GA mutations, suggesting that a second round of editing may be occurring on mRNA 310 
transcribed from the mutated DNA (Figure 5F); yet, the main editing appeared to be 311 
occurring on the viral DNA which was mirrored by the mutations observed in viral cDNA 312 
(Figure 5B and 5C).  In looking at the type of mutations arising from 39 commonly 313 
mutated positions in UL54 cDNA and 30 commonly mutated positions in UL54 DNA, 314 
approximately 70% of mutations were found to lead to non-synonymous substitutions in 315 
the analyzed gene (Figure 5G). 316 
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APOBECs, such as A3G, are known to have an editing preference for 5’CpC and 5’TpC 317 
and we attempted to assess the dinucleotide preference of rat A1 (58).  As can be seen 318 
in Figure 5H, we found the preferred context to be 5’GpC on both viral DNA and RNA, 319 
although previous studies have indicated a tendency of rodent A1 to prefer 5’TpC 320 
(Figure 5H) (11, 28, 48). Altogether, these results indicate that rat A1 directly acts on 321 
DNA for editing. 322 
A1 inhibits HSV-1 transcription independently of viral mRNA editing  323 
To further elucidate the mechanism by which A1 inhibits HSV-1 infection, we focused on 324 
the initial transcription of viral genes in the presence of the nucleoside analogue 325 
inhibitor, acyclovir, which effectively inhibits nascent DNA synthesis.  If A1 mainly acts 326 
on ssDNA substrates for mutagenesis then we expected to see reduced deamination of 327 
HSV-1 cDNA during transcription and few clones harboring signature A1-mediated 328 
mutations.  At a MOI of 1, the sequencing of UL54 mRNA extracted 2 hpi revealed a low 329 
frequency of C  U and G  A transitions in samples taken from A1WT expressing cells 330 
similar to nucleic acids obtained from A1Ctrl, further indicating that A1 is acting on DNA 331 
and not mRNA (Figure 6A and 6B).  In addition, only 1 clone containing these mutations 332 
was observed from each A1Ctrl and A1WT RSC (Figure 6C and 6D).   However, when we 333 
looked at the levels of viral gene transcripts at this time point, α, β, and γ gene 334 
expression was still significantly lower in A1WT than A1Ctrl RSC (Figure 6E).  Altogether, 335 
these data suggest that although A1 did not induce mutations in viral RNA, its 336 




From our findings, we propose a novel role for A1 as an inhibitor of HSV-1 infection in 339 
the context of HSE in rats. Although the induction mechanism remains to be elucidated, 340 
we posit that HSV-1 infection triggers the expression of A1 in neuronal cells which 341 
inhibits the early stages of the virus life cycle. The molecule may edit viral DNA in the 342 
nucleus, and/or serve as a physical blockade by binding to DNA during transcription, 343 
resulting in reduced expression and dysfunction of the edited viral genes.  Stalling of the 344 
HSV-1 gene cascade may prevent the virus from ramping up to full scale production 345 
and allow for a controlled immune response. 346 
We found that both viral DNA and RNA harbored G  A transitions, however, DNA was 347 
the main target of A1 during HSV-1 infection (Figure 5B and 5C).  Furthermore, when 348 
DNA synthesis was blocked, cDNA isolated from virus-infected cells displayed few 349 
mutations, further reinforcing the assumption that A1 is acting on a DNA substrate 350 
(Figure 6A and 6B).   HSV-1 is known to replicate within the nucleus and while A1 has 351 
been reported to shuttle between the cytosol and nucleus in the presence of apobec 1 352 
complementation factor (ACF) for a nuclear distribution, if ACF is mutated or absent, 353 
then A1 will primarily have a cytoplasmic localization (9, 24). Here, we show similar 354 
distribution of A1 in the cytosol in vivo in HSV-1-infected neurons and in vitro in A1 355 
expressing RSC (Figure 2B and 3B). Yet, because we observed mutations in HSV-1 356 
DNA in vitro (Figure 5B), this suggests that a small pool of A1 also exists in the nucleus 357 
and is involved in the direct interaction with and mutation of genomic viral DNA. 358 
Although we obtained evidence of cytidine deaminase dependent mutations in HSV-1 359 
nucleic acids, it is possible that our observed results could be an underestimate of the 360 
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actual degree of mutagenesis which is taking place inside of A1-expressing cells.  HSV 361 
encodes a uracil DNA glycosylase which is able to remove uracil bases from DNA 362 
allowing for subsequent repair of the damaged DNA (31, 37, 62).  This activity may be 363 
masking the true extent of deamination taking place by A1.   364 
It is worth noting that the editing of HSV-1 DNA alone may not completely account for 365 
the inhibition of HSV-1. We found 33% of mutated positions in the sequenced region of 366 
UL54 DNA and 28% of UL54 RNA to be synonymous mutations, meaning that their 367 
function would remain intact (Figure 5G). Furthermore, mutations alone do not entirely 368 
account for the observed inhibition of α gene transcription (Figure 4A) since 369 
transcription of these genes are highly dependent on incoming tegument protein VP16  370 
which acts as a transactivator (1, 2). Therefore, it is possible that A1 may also inhibit 371 
gene transcription through an undefined mechanism similar to the A3 deaminase-372 
independent inhibition of HIV-1 reverse transcription products, perhaps through a 373 
physical block of transcription or DNA replication (6, 18, 19, 40, 56).  Supporting this 374 
assumption is data from our deaminase-deficient mutant AE63A that showed partial 375 
inhibition of HSV-1 infection, although not to the same extent as the A1WT protein 376 
(Figure 3C and 3E).  Moreover, diminished HSV-1 transcript levels were observed in 377 
A1WT RSC when DNA synthesis was inhibited, even in the absence of RNA cytidine 378 
deamination (Figure 6E).  Yet, because of the presence of repair mechanisms encoded 379 
by HSV-1, such as the uracil DNA glycosylase described above, we were not able to 380 
rule out the possibility that viral ssDNA is mutated during transcription.   381 
If mutated viral transcripts are synthesized and make their way to the cytoplasm for 382 
translation, we suspect the functionality of the synthesized viral protein may be affected.  383 
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As mentioned above, the gene expression of HSV-1 is tightly regulated and defects in 384 
certain genes can have detrimental effects on the virus life cycle. For instance, studies 385 
on HSV-1 temperature mutants have revealed that defects in the IE genes ICP4, and 386 
UL54 render the virus replication deficient (16, 46, 50). Furthermore, IE genes have 387 
pleiotropic functions as transcriptional activators of viral genes and suppressors of host 388 
protein synthesis. In the case of UL54, other functions include the inhibition of mRNA 389 
splicing, an increase in viral mRNA levels, and the export of viral mRNA from the 390 
nucleus (10, 20, 29, 51, 52). Given that HSV-1 proteins have essential regulatory roles, 391 
it is conceivable that disruptions of these genes can cause a stall in the virus replication 392 
cycle.  Our results also support this possibility as evidenced by the reduced HSV-1 393 
mRNA and DNA levels, GFP expression, and virus titer in infected A1 expressing RSC 394 
(Figure 3C, 3E, 4A, and 4B, respectively). This effect was dependent on A1 expression 395 
as silencing of A1 by specific shRNA restored HSV-1 infection (Figure 3D). 396 
Our in vitro results raise the issue of whether the expression of A1 in rat brains induced 397 
during HSE aids to inhibit virus infection or not. Rat A1 is ubiquitously expressed in 398 
virtually all tissues such as the spleen and liver and while A1 functions within an editing 399 
complex in the small intestine for the deamination of apolipoprotein B mRNA, it is also 400 
expressed in tissues where apolipoprotein B mRNA is not present, bringing into 401 
question whether there is an additional role for this enzyme (25). Indications that A1 402 
also has antiviral activity on top of its already known physiological function have been 403 
shown using mouse models infected with either MLV or HBV. Splenocytes taken from 404 
MLV infected mice or hepatocytes taken from HBV infected transgenic mice both 405 
displayed signs of A1 specific editing of viral genomes, implicating a direct role in virus 406 
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inhibition (44, 48). From our in vivo findings, survived and mild rats showed an increase 407 
in A1 mRNA expression which was not observed in mock infected rats (Figure 2A and 408 
2B). Moreover, rat brain tissue infected by HSV-1 revealed that the induction of A1 409 
occurred predominantly in HSV-1 infected neuronal cells and suggests a possible 410 
antiviral function for this molecule in the brain. 411 
The consequence of increased cytidine deamination of the HSV-1 genome on virus 412 
infectivity has been exemplified by a previous report showing that HSV-1 mutants 413 
containing a defective uracil DNA glycosylase were 100,000 times less neuroinvasive in 414 
mice intracranially inoculated with HSV-1 than their wild type counterparts (47).  On the 415 
other hand, uracil DNA glycosylase deficient-HSV-1 did not have issues replicating in 416 
vitro, suggesting that this enzyme is necessary for virus infectivity in rodent neurons 417 
because HSV-1 is more prone to cytidine deamination in these cells (47).  It is tempting 418 
to speculate that A1 in rats may also be playing a role in mutating the HSV-1 DNA in 419 
vivo to inhibit HSV-1 infection in the brain in our model.    420 
A1 may also help to reduce HSE in vivo by slowing down virus dissemination long 421 
enough to allow for an appropriate immune response to be mounted, thus eliminating 422 
the virus without causing excessive damage from infiltrating macrophages during 423 
encephalitis or lytic damage resulting from massive viral infection. In fact, it has been 424 
speculated that an overzealous immune response may be causing more harm than 425 
good in the CNS (13). For instance, the depletion of macrophages during HSV-1 426 
infection in mice has been demonstrated to lead to a higher survival rate (33). On the 427 
other hand, uncontrolled virus dissemination can also lead to a fatal outcome in mice 428 
missing type I interferon receptor (14, 32). Needless to say, a balance must be struck 429 
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between the host immune response and the extent of virus infection. It is plausible that 430 
A1 helps to achieve both of these feats by inhibiting virus infection, resulting in a toned 431 
down immune response, as was shown in vitro (Figure 3C and 3E). Here, we observed 432 
diminished leukocyte infiltration in survived rats compared to mild and severe rats which 433 
died within 5-6 days after infection in our in vivo model (Figure 1A). Moreover, HSV-1 434 
infected areas, diminished over time in survived rats, suggesting the containment of 435 
virus dissemination (Figure 1C). 436 
In conclusion, we identified rat A1 as a novel anti-HSV-1 molecule induced during virus 437 
infection in rat brains. The mechanism by which A1 inhibits virus replication appears to 438 
be through the interference of the HSV-1 gene cascade by a predominantly deaminase 439 
dependent manner involving the editing of viral DNA. In order to assess the extent of A1 440 
inhibition on HSV-1 infection during encephalitis, future studies using knockout animals 441 
may provide insights into the contribution of A1 in controlling HSE.       442 
22 
 
Acknowledgments. We would like to thank Atsushi Koito, Youichi Suzuki, and Kei Sato 443 
for their generous support in our study, and Bernard Roizman for providing us with the 444 
RSC. This work was supported in-part by a Grant-in-Aid for Scientific Research on 445 
Priority Areas “Matrix of Infection Phenomena” [18073008 to Y.K.] from the Ministry of 446 
Education, Culture, Sports, Science and Technology (MEXT) of Japan; Research on 447 
HIV/AIDS [200932025A to Y.K.] from the Ministry of Health, Labor and Welfare of 448 
Japan; P.G. was supported by the foreign student program by MEXT. 449 
Footnotes 450 
Author contributions: Y.K., Y.A., H.K., and P.G. designed research; Y.A., H.K., S.P.Y., 451 
Y.K., H.E., and P.G. performed research; Y.K. contributed new reagents/analytic tools; 452 
Y.K., Y.A., H.K., and P.G. analyzed data; and Y.K. and P.G. wrote the paper. 453 




1. Ace, C. I., M. A. Dalrymple, F. H. Ramsay, V. G. Preston, and C. M. Preston. 456 
1988. Mutational analysis of the herpes simplex virus type 1 trans-inducing factor 457 
Vmw65. J Gen Virol 69 ( Pt 10):2595-605. 458 
2. Ace, C. I., T. A. McKee, J. M. Ryan, J. M. Cameron, and C. M. Preston. 1989. 459 
Construction and characterization of a herpes simplex virus type 1 mutant unable 460 
to transinduce immediate-early gene expression. J Virol 63:2260-9. 461 
3. Alce, T. M., and W. Popik. 2004. APOBEC3G is incorporated into virus-like 462 
particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 463 
279:34083-6. 464 
4. Ando, Y., H. Kitayama, Y. Kawaguchi, and Y. Koyanagi. 2008. Primary target 465 
cells of herpes simplex virus type 1 in the hippocampus. Microbes Infect 466 
10:1514-23. 467 
5. Bergstrom, T., B. Svennerholm, N. Conradi, P. Horal, and A. Vahlne. 1991. 468 
Discrimination of herpes simplex virus types 1 and 2 cerebral infections in a rat 469 
model. Acta Neuropathol 82:395-401. 470 
6. Bishop, K. N., R. K. Holmes, and M. H. Malim. 2006. Antiviral potency of 471 
APOBEC proteins does not correlate with cytidine deamination. J Virol 80:8450-8. 472 
7. Bishop, K. N., R. K. Holmes, A. M. Sheehy, N. O. Davidson, S. J. Cho, and M. 473 
H. Malim. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC 474 
proteins. Curr Biol 14:1392-6. 475 
8. Bishop, K. N., R. K. Holmes, A. M. Sheehy, and M. H. Malim. 2004. APOBEC-476 
mediated editing of viral RNA. Science 305:645. 477 
9. Blanc, V., J. O. Henderson, S. Kennedy, and N. O. Davidson. 2001. 478 
Mutagenesis of apobec-1 complementation factor reveals distinct domains that 479 
modulate RNA binding, protein-protein interaction with apobec-1, and 480 
complementation of C to U RNA-editing activity. J Biol Chem 276:46386-93. 481 
10. Chen, I. H., K. S. Sciabica, and R. M. Sandri-Goldin. 2002. ICP27 interacts 482 
with the RNA export factor Aly/REF to direct herpes simplex virus type 1 483 
intronless mRNAs to the TAP export pathway. J Virol 76:12877-89. 484 
11. Chen, Z., T. L. Eggerman, A. V. Bocharov, I. N. Baranova, T. G. Vishnyakova, 485 
G. Csako, and A. P. Patterson. 2010. Hypermutation induced by APOBEC-1 486 
overexpression can be eliminated. RNA 16:1040-52. 487 
12. Conley, A. J., D. M. Knipe, P. C. Jones, and B. Roizman. 1981. Molecular 488 
genetics of herpes simplex virus. VII. Characterization of a temperature-sensitive 489 
mutant produced by in vitro mutagenesis and defective in DNA synthesis and 490 
accumulation of gamma polypeptides. J Virol 37:191-206. 491 
13. Conrady, C. D., D. A. Drevets, and D. J. Carr. 2010. Herpes simplex type I 492 
(HSV-1) infection of the nervous system: is an immune response a good thing? J 493 
Neuroimmunol 220:1-9. 494 
14. Conrady, C. D., M. Thapa, T. Wuest, and D. J. Carr. 2009. Loss of mandibular 495 
lymph node integrity is associated with an increase in sensitivity to HSV-1 496 
infection in CD118-deficient mice. J Immunol 182:3678-87. 497 
15. Crawford, J. P., D. H. Percy, and L. A. Hatch. 1979. Experimental encephalitis 498 
in the newborn rat due to herpes simplex virus type 2. Exp Mol Pathol 31:44-55. 499 
24 
 
16. DeLuca, N. A., M. A. Courtney, and P. A. Schaffer. 1984. Temperature-500 
sensitive mutants in herpes simplex virus type 1 ICP4 permissive for early gene 501 
expression. J Virol 52:767-76. 502 
17. Driscoll, D. M., and Q. Zhang. 1994. Expression and characterization of p27, 503 
the catalytic subunit of the apolipoprotein B mRNA editing enzyme. J Biol Chem 504 
269:19843-7. 505 
18. Gaddis, N. C., E. Chertova, A. M. Sheehy, L. E. Henderson, and M. H. Malim. 506 
2003. Comprehensive investigation of the molecular defect in vif-deficient human 507 
immunodeficiency virus type 1 virions. J Virol 77:5810-20. 508 
19. Guo, F., S. Cen, M. Niu, J. Saadatmand, and L. Kleiman. 2006. Inhibition of 509 
formula-primed reverse transcription by human APOBEC3G during human 510 
immunodeficiency virus type 1 replication. J Virol 80:11710-22. 511 
20. Hardwicke, M. A., and R. M. Sandri-Goldin. 1994. The herpes simplex virus 512 
regulatory protein ICP27 contributes to the decrease in cellular mRNA levels 513 
during infection. J Virol 68:4797-810. 514 
21. Hardy, W. R., and R. M. Sandri-Goldin. 1994. Herpes simplex virus inhibits host 515 
cell splicing, and regulatory protein ICP27 is required for this effect. J Virol 516 
68:7790-9. 517 
22. Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen-Mahrt, I. 518 
N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deamination mediates 519 
innate immunity to retroviral infection. Cell 113:803-9. 520 
23. Harris, R. S., S. K. Petersen-Mahrt, and M. S. Neuberger. 2002. RNA editing 521 
enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 522 
10:1247-53. 523 
24. Henderson, J. O., V. Blanc, and N. O. Davidson. 2001. Isolation, 524 
characterization and developmental regulation of the human apobec-1 525 
complementation factor (ACF) gene. Biochim Biophys Acta 1522:22-30. 526 
25. Hirano, K., J. Min, T. Funahashi, and N. O. Davidson. 1997. Cloning and 527 
characterization of the rat apobec-1 gene: a comparative analysis of gene 528 
structure and promoter usage in rat and mouse. J Lipid Res 38:1103-19. 529 
26. Honess, R. W., and B. Roizman. 1974. Regulation of herpesvirus 530 
macromolecular synthesis. I. Cascade regulation of the synthesis of three groups 531 
of viral proteins. J Virol 14:8-19. 532 
27. Huthoff, H., and M. H. Malim. 2007. Identification of amino acid residues in 533 
APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif 534 
and Virion encapsidation. J Virol 81:3807-15. 535 
28. Ikeda, T., T. Ohsugi, T. Kimura, S. Matsushita, Y. Maeda, S. Harada, and A. 536 
Koito. 2008. The antiretroviral potency of APOBEC1 deaminase from small 537 
animal species. Nucleic Acids Res 36:6859-71. 538 
29. Jean, S., K. M. LeVan, B. Song, M. Levine, and D. M. Knipe. 2001. Herpes 539 
simplex virus 1 ICP27 is required for transcription of two viral late (gamma 2) 540 
genes in infected cells. Virology 283:273-84. 541 
30. Kitayama, H., Y. Miura, Y. Ando, and Y. Koyanagi. 2008. Human 542 
immunodeficiency virus type-1 vulnerates nascent neuronal cells. Microbiol 543 
Immunol 52:78-88. 544 
25 
 
31. Lindahl, T. 1979. DNA glycosylases, endonucleases for apurinic/apyrimidinic 545 
sites, and base excision-repair. Prog Nucleic Acid Res Mol Biol 22:135-92. 546 
32. Luker, G. D., J. L. Prior, J. Song, C. M. Pica, and D. A. Leib. 2003. 547 
Bioluminescence imaging reveals systemic dissemination of herpes simplex virus 548 
type 1 in the absence of interferon receptors. J Virol 77:11082-93. 549 
33. Lundberg, P., C. Ramakrishna, J. Brown, J. M. Tyszka, M. Hamamura, D. R. 550 
Hinton, S. Kovats, O. Nalcioglu, K. Weinberg, H. Openshaw, and E. M. 551 
Cantin. 2008. The immune response to herpes simplex virus type 1 infection in 552 
susceptible mice is a major cause of central nervous system pathology resulting 553 
in fatal encephalitis. J Virol 82:7078-88. 554 
34. Mahieux, R., R. Suspene, F. Delebecque, M. Henry, O. Schwartz, S. Wain-555 
Hobson, and J. P. Vartanian. 2005. Extensive editing of a small fraction of 556 
human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine 557 
deaminases. J Gen Virol 86:2489-94. 558 
35. Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono. 2003. 559 
Broad antiretroviral defence by human APOBEC3G through lethal editing of 560 
nascent reverse transcripts. Nature 424:99-103. 561 
36. Mehta, A., and D. M. Driscoll. 1998. A sequence-specific RNA-binding protein 562 
complements apobec-1 To edit apolipoprotein B mRNA. Mol Cell Biol 18:4426-32. 563 
37. Mullaney, J., H. W. Moss, and D. J. McGeoch. 1989. Gene UL2 of herpes 564 
simplex virus type 1 encodes a uracil-DNA glycosylase. J Gen Virol 70 ( Pt 565 
2):449-54. 566 
38. Navaratnam, N., S. Bhattacharya, T. Fujino, D. Patel, A. L. Jarmuz, and J. 567 
Scott. 1995. Evolutionary origins of apoB mRNA editing: catalysis by a cytidine 568 
deaminase that has acquired a novel RNA-binding motif at its active site. Cell 569 
81:187-95. 570 
39. Navaratnam, N., J. R. Morrison, S. Bhattacharya, D. Patel, T. Funahashi, F. 571 
Giannoni, B. B. Teng, N. O. Davidson, and J. Scott. 1993. The p27 catalytic 572 
subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J 573 
Biol Chem 268:20709-12. 574 
40. Newman, E. N., R. K. Holmes, H. M. Craig, K. C. Klein, J. R. Lingappa, M. H. 575 
Malim, and A. M. Sheehy. 2005. Antiviral function of APOBEC3G can be 576 
dissociated from cytidine deaminase activity. Curr Biol 15:166-70. 577 
41. Noguchi, C., H. Ishino, M. Tsuge, Y. Fujimoto, M. Imamura, S. Takahashi, 578 
and K. Chayama. 2005. G to A hypermutation of hepatitis B virus. Hepatology 579 
41:626-33. 580 
42. Okeoma, C. M., N. Lovsin, B. M. Peterlin, and S. R. Ross. 2007. APOBEC3 581 
inhibits mouse mammary tumour virus replication in vivo. Nature 445:927-30. 582 
43. Petersen-Mahrt, S. K., and M. S. Neuberger. 2003. In vitro deamination of 583 
cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex 584 
catalytic subunit 1 (APOBEC1). J Biol Chem 278:19583-6. 585 
44. Petit, V., D. Guetard, M. Renard, A. Keriel, M. Sitbon, S. Wain-Hobson, and J. 586 
P. Vartanian. 2009. Murine APOBEC1 is a powerful mutator of retroviral and 587 
cellular RNA in vitro and in vivo. J Mol Biol 385:65-78. 588 
26 
 
45. Powell, L. M., S. C. Wallis, R. J. Pease, Y. H. Edwards, T. J. Knott, and J. 589 
Scott. 1987. A novel form of tissue-specific RNA processing produces 590 
apolipoprotein-B48 in intestine. Cell 50:831-40. 591 
46. Preston, C. M. 1979. Control of herpes simplex virus type 1 mRNA synthesis in 592 
cells infected with wild-type virus or the temperature-sensitive mutant tsK. J Virol 593 
29:275-84. 594 
47. Pyles, R. B., and R. L. Thompson. 1994. Evidence that the herpes simplex 595 
virus type 1 uracil DNA glycosylase is required for efficient viral replication and 596 
latency in the murine nervous system. J Virol 68:4963-72. 597 
48. Renard, M., M. Henry, D. Guetard, J. P. Vartanian, and S. Wain-Hobson. 598 
2010. APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for 599 
hepadnaviral genomes in non-humans in vivo. J Mol Biol 400:323-34. 600 
49. Rosler, C., J. Kock, M. Kann, M. H. Malim, H. E. Blum, T. F. Baumert, and F. 601 
von Weizsacker. 2005. APOBEC-mediated interference with hepadnavirus 602 
production. Hepatology 42:301-9. 603 
50. Sacks, W. R., C. C. Greene, D. P. Aschman, and P. A. Schaffer. 1985. Herpes 604 
simplex virus type 1 ICP27 is an essential regulatory protein. J Virol 55:796-805. 605 
51. Sandri-Goldin, R. M. 1998. ICP27 mediates HSV RNA export by shuttling 606 
through a leucine-rich nuclear export signal and binding viral intronless RNAs 607 
through an RGG motif. Genes Dev 12:868-79. 608 
52. Sandri-Goldin, R. M. 1994. Properties of an HSV-1 regulatory protein that 609 
appears to impair host cell splicing. Infect Agents Dis 3:59-67. 610 
53. Sato, K., T. Izumi, N. Misawa, T. Kobayashi, Y. Yamashita, M. Ohmichi, M. 611 
Ito, A. Takaori-Kondo, and Y. Koyanagi. 2010. Remarkable lethal G-to-A 612 
mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in 613 
humanized mice. J Virol 84:9546-56. 614 
54. Schafer, A., H. P. Bogerd, and B. R. Cullen. 2004. Specific packaging of 615 
APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the 616 
gag polyprotein precursor. Virology 328:163-8. 617 
55. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a 618 
human gene that inhibits HIV-1 infection and is suppressed by the viral Vif 619 
protein. Nature 418:646-50. 620 
56. Shindo, K., A. Takaori-Kondo, M. Kobayashi, A. Abudu, K. Fukunaga, and T. 621 
Uchiyama. 2003. The enzymatic activity of CEM15/Apobec-3G is essential for 622 
the regulation of the infectivity of HIV-1 virion but not a sole determinant of its 623 
antiviral activity. J Biol Chem 278:44412-6. 624 
57. Suspene, R., D. Guetard, M. Henry, P. Sommer, S. Wain-Hobson, and J. P. 625 
Vartanian. 2005. Extensive editing of both hepatitis B virus DNA strands by 626 
APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A 627 
102:8321-6. 628 
58. Suspene, R., P. Sommer, M. Henry, S. Ferris, D. Guetard, S. Pochet, A. 629 
Chester, N. Navaratnam, S. Wain-Hobson, and J. P. Vartanian. 2004. 630 
APOBEC3G is a single-stranded DNA cytidine deaminase and functions 631 
independently of HIV reverse transcriptase. Nucleic Acids Res 32:2421-9. 632 
27 
 
59. Tanaka, M., H. Kodaira, Y. Nishiyama, T. Sata, and Y. Kawaguchi. 2004. 633 
Construction of recombinant herpes simplex virus type I expressing green 634 
fluorescent protein without loss of any viral genes. Microbes Infect 6:485-93. 635 
60. Teng, B., C. F. Burant, and N. O. Davidson. 1993. Molecular cloning of an 636 
apolipoprotein B messenger RNA editing protein. Science 260:1816-9. 637 
61. Whitley, R. J. 2006. Herpes simplex encephalitis: adolescents and adults. 638 
Antiviral Res 71:141-8. 639 
62. Worrad, D. M., and S. Caradonna. 1988. Identification of the coding sequence 640 
for herpes simplex virus uracil-DNA glycosylase. J Virol 62:4774-7. 641 
63. Yu, Q., R. Konig, S. Pillai, K. Chiles, M. Kearney, S. Palmer, D. Richman, J. 642 
M. Coffin, and N. R. Landau. 2004. Single-strand specificity of APOBEC3G 643 



























Scale bar, 200 µm
B CCD3 / GFP CD68 / GFP
Figure 1. HSE model induced by GFP-HSV-1 inoculation of infant rats. Fourteen day-old infant rats were intracranially injected with GFP-
expressing HSV-1 (YK333), and brain tissues were collected from rats exhibiting severe or mild encephalitis as described in Table 1 or from 
survived rats 36 h after the disappearance of paralysis. PBS (Mock)-inoculated rats were used as negative controls and brain tissues were collected 
at the end of the experiment. (A) GFP+ (green) regions in the coronal plane, HE, GFP+ (green) and HSV antigen+ (red) brain cells in the tissue 
section. Nuclei were also stained with Hoechst33342 (blue) and shown in the merged image. A zoom in view of the rectangular region in the merged 
image is shown to the right. (B) GFP+ (green), CD3+ (red) or CD68+ (red) cells in the tissue section. (C) GFP+ regions in the coronal plane 
(right panels) and GFP+ and HSV antigen+ cells in the tissue section (left panels) are shown in survived rats at indicated h after the disappearance 












































































































Scale bars, 40 µm
Figure 2. Expression of A1 in HSV-1-infected rat brains. (A) The level of A1 cDNA expression quantified by real-time PCR in the brain and small intestine of HSV-1-inoculated 
rats, which consisted of 4 mild rats and 2 recovery rats, and of 4 PBS-inoculated rats was assessed.  (B) A1+ (red), GFP+ (green), and MAP2+ (blue) neuronal cells of an HSV-1 
and mock-infected rat brain (upper panels) and A1+ cells in the small intestine of HSV-1 and mock-infected rats (bottom panels). Representative results are shown. Scale bars are 
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Figure 3. A1 inhibits HSV-1 infection. (A) Western blotting of HA-tagged WT, E63A, and Ctrl stably transfected cells probed with an anti-HA for A1 
expression or an anti-tubulin antibody an an internal standard. (B) Immunofluorescence staining of HA-tagged A1WT, A1E63A or A1Ctrl RSC with an 
anti-HA antibody (green).  The nucleus was stained with Hoechst33342 (blue). (C) Longitudinal analysis of GFP-expressing HSV-1 infection in A1WT, 
A1E63A mutant, or Control stably transfected cells. **, P<0.05 and ***P<0.005. (D) Level of GFP in HA-tagged A1WT RSC stably expressing A1 
targeted shRNAs or luciferase (Luc) 48 h after YK333 infection. ***P<0.005 compared to shLuc-treated cells.  Western blot probed with an anti-HA 
antibody for the expression of A1 and anti-tubulin as an internal standard. (E) Level of PFU in the supernatant of Ctrl, WT, and E63A RSC 48 h after the 




















































































Figure 4.  Inhibition of HSV-1 mRNA and DNA.  (A) HSV-1 gene 
expression for UL54, UL30, and UL27 were measured by real-time PCR 
and normalized to GAPDH.  Nucleic acids were extracted from HSV-1 
infected WT and Ctrl RSC 8 hpi.   (B) DNA copy number was measured by
real-time PCR in A1 and control RSC 4 and 8 h after infection.  As a control, 
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Figure 5. Sequencing analysis of UL54 DNA and cDNA from A1WT and A1
Ctrl HSV-1 infected RSC.  A 399 bp region of UL54 DNA or cDNA, extracted 
8 hpi, was amplified by nested PCR and cloned for sequencing.  Mutation 
matrices are depicted for (A) DNA extracted from A1Ctrl RSC, 51 clones; 
(B) DNA extracted from A1WT RSC, 51 clones; and (C) cDNA extracted 
from A1WT RSC, 58 clones.  The number of clones harboring G to A and 
C to T transitions was assessed and represented in (D) DNA extracted from A1
Ctrl RSC; (E) DNA extracted from A1WT RSC; and (F) cDNA extracted from 
A1WT RSC.  (G) Mutations from UL54 cDNA and DNA were narrowed down 
to 39 and 30 commonly mutated positions, respectively.  The % of 
synonymous or non-synonymous mutations is depicted in the bar graph.  
(H) Rat A1 had a tendency in dinucleotide context for 5’GpC in viral UL54 
DNA and cDNA and was statistically significant in the DNA.  A χ2 analysis 
showed that when compared to expected values, 5’GpC was significantly 
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Figure 6. A1 inhibition of HSV-1 RNA transcripts is independent of RNA 
mutagenesis.  A1WT and A1Ctrl RSC were infected with YK333 at a MOI 
of 1 for 2 h in the presence of 25 μg/mL of acyclovir.  Mutation matrices for 
UL54 cDNA extracted from (A) A1Ctrl RSC and (B) A1WT RSC are shown.    
The number of clones harboring G to A and C to T transitions from (C) cDNA 
extracted from A1Ctrl RSC, 20 colonies and (D) cDNA extracted from A1WT 
RSC, 21 colonies, was assessed and represented in the bar graphs. (E) The level 
of HSV-1 mRNA for UL54, UL30 and UL27 in A1Ctrl and A1WT RSC were 
measured by real time PCR and normalized to GAPDH levels.  *, p< 0.05; 
**, p<0.0005; ***, p<0.00005.







a     HSV-1-infected rats were classified as follows: Severe, which died within 5 days after showing symptoms of severe encephalitis; Mild, which 
died between 5-7 days after showing symptoms of mild encephalitis; Survived, which recovered after transient encephalitis; Healthy, which did not 
display HSE symptoms. 
b     The number of rats exhibiting neurological symptoms such as monoplegia, quadriplegia, and seizures. 
c     The percentage of damaged areas including cell loss, degeneration of cells, and/or hemorrhaging in the coronal section was presented as 
follows: -, <5%; +, 5-10%; ++, > 15% 
d     The number of CD3-positive cells in one infected area of the coronal section was quantified and presented as follows: -, not detected; +, <5 
cells; ++, 5-20 cells; +++, >20 cells. 
e     The number of CD68-positive cells in one infected area of the coronal section was quantified and presented as follows: -, not detected; +, <5 
cells; ++, 5-50 cells; +++, >50 cells. 






Number of rats showing the following 












Severe 17 (27) 1 15 11 + ++ ++ ++ ++ 
Mild 14 (22.2) 7 7 4 ++ +++ +++ +++ +++ 
Survived 24 (38.1) 22 0 0 - + + + + 
Healthy 8 (12.7) 0 0 0 - - - - - 
Total 63                   
